These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18535834)

  • 1. Current aspects of targeted therapy in head and neck tumors.
    Dietz A; Boehm A; Mozet C; Wichmann G; Giannis A
    Eur Arch Otorhinolaryngol; 2008 Jul; 265 Suppl 1():S3-12. PubMed ID: 18535834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-targeting monoclonal antibodies in head and neck cancer.
    Astsaturov I; Cohen RB; Harari PM
    Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.
    Markovic A; Chung CH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1149-59. PubMed ID: 23098115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Pomerantz RG; Grandis JR
    Curr Oncol Rep; 2003 Mar; 5(2):140-6. PubMed ID: 12583831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy in head and neck cancer.
    Kundu SK; Nestor M
    Tumour Biol; 2012 Jun; 33(3):707-21. PubMed ID: 22373581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.
    Harari PM; Wheeler DL; Grandis JR
    Semin Radiat Oncol; 2009 Jan; 19(1):63-8. PubMed ID: 19028347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
    Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL
    Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.
    van Dijk LK; Boerman OC; Kaanders JH; Bussink J
    Clin Cancer Res; 2015 Aug; 21(16):3602-9. PubMed ID: 25931452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence.
    Benson R; Mallick S; Julka PK; Rath GK
    J Egypt Natl Canc Inst; 2016 Sep; 28(3):141-8. PubMed ID: 27160750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.